Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs

2010384 citationsJournal Articlebronze Open Access

Authors

Hervé Decousus · Université Jean Monnet

P. Prandoni · University of Padua

Patrick Mismetti · Université Jean Monnet

Rupert Bauersachs · Klinikum Darmstadt

Z Boda · University of Debrecen

Benjamin Brenner · Rambam Health Care Campus

Silvy Laporte ·

Abstract

Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00443053.)

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Diagnosis and Treatment of Venous Diseases Atrial Fibrillation Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 13, pp. 1222-1232

DOI: 10.1056/nejmoa0912072

Field-Weighted Citation Impact: 20.17